Emerging Clinical Activity of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Follicular Lymphoma (FL), Diffuse Large B-Cell Lymphoma (DLBCL), and Other B-Cell Non-Hodgkin Lymphoma (B-NHL) Subtypes

被引：12

作者：

Bannerji, Rajat ^{[1
]}

Arnason, Jon E. ^{[2
]}

Advani, Ranjana ^{[3
]}

Brown, Jennifer R. ^{[4
]}

Allan, John N. ^{[5
]}

Ansell, Stephen M. ^{[6
]}

Barnes, Jeffrey ^{[7
]}

O'Brien, Susan M. ^{[8
]}

Chavez, Julio C. ^{[9
]}

Duell, Johannes ^{[10
]}

Lowy, Israel ^{[11
]}

Charnas, Robert ^{[11
]}

Sternberg, David ^{[11
]}

Ambati, Srikanth ^{[11
]}

Adriaens, Lieve ^{[12
]}

Ufkin, Melanie ^{[11
]}

Yan, Xiaoyu ^{[11
]}

Li, Jingjin ^{[12
]}

Navarro, Mark ^{[11
]}

Gasparini, Peter ^{[11
]}

Jankovic, Vladimir ^{[11
]}

Fiaschi, Nathalie ^{[11
]}

Zhang, Wen ^{[11
]}

Hamon, Sara ^{[11
]}

Thurston, Gavin ^{[11
]}

Topp, Max S. ^{[10
]}

机构：

[1] Canc Inst New Jersey, New Brunswick, NJ USA

[2] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA

[3] Stanford Univ, Stanford, CA 94305 USA

[4] Dana Farber Canc Inst, Boston, MA 02115 USA

[5] Weill Cornell Med, Div Hematol & Oncol, New York, NY USA

[6] Mayo Clin, Div Hematol, Rochester, MN USA

[7] Massachusetts Gen Hosp, Boston, MA 02114 USA

[8] Univ Calif Irvine, Irvine, CA USA

[9] H Lee Moffitt Canc Ctr & Res Inst, Dept Malignant Hematol, Tampa, FL USA

[10] Univ Hosp Wurzburg, Wurzburg, Germany

[11] Regeneron Pharmaceut Inc, Tarrytown, NY USA

[12] Regeneron Pharmaceut Inc, Basking Ridge, NJ USA

来源：

BLOOD | 2018年 / 132卷

关键词：

D O I：

10.1182/blood-2018-99-113328

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1690

引用

页数：5

共 50 条

[31] A multicenter phase II study of vorinostat in patients (pts) with relapsed or refractory indolent B-cell non-Hodgkin lymphoma (B-NHL) or mantle cell lymphoma (MCL).
Ando, Kiyoshi
Ogura, Michinori
Suzuki, Tatsuya
Ishizawa, Kenichi
Oh, Sung Yong
Kim, Won Seog
Tanaka, Yoshinobu
Shimamoto, Takashi
Tobinai, Kensei
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[32] A CD19/CD20-Directed Bispecific CAR-T Cell Therapy in Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma (NHL)
Larson, Sarah M.
Chen, Yvonne Y.
Johnston, Jim
Roy, Sylvain
Patel, Pinakin
Benjamin, Jonathan E.
BLOOD, 2023, 142
[33] Lenalidomide response in relapsed/refractory diffuse large B-cell non-Hodgkin's lymphoma
Lossos, Izidore S.
Wiernik, Peter H.
Justice, Glen
Tuscano, Joseph M.
Cole, Craig E.
Vose, Julie M.
Pietronigro, Dennis
Takeshita, Kenichi
Ervin-Haynes, Annette
Zeldis, Jerome B.
Habermann, Thomas M.
BLOOD, 2007, 110 (11) : 756A - 756A
[34] Results of A Phase 1 Study of Milatuzumab, a Humanized Anti-CD74 Antibody, and Veltuzumab, a Humanized Anti-CD20 Antibody, In Patients with Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma
Christian, Beth
Alinari, Lapo
Jones, Jeffrey A.
Benson, Don M., Jr.
Flynn, Joseph M.
Porcu, Pierluigi
Lustberg, Mark E.
Phelps, Mitchell
Poi, Ming
Chung, Diana
Quinion, Carl
Byrd, John C.
Wegener, William
Goldenberg, David M.
Baiocchi, Robert A.
Blum, Kristie A.
BLOOD, 2011, 118 (21) : 1584 - 1584
[35] Phase I and pharmacokinetics study of a novel anti-CD20 antibody, RO5072759 (GA101), in Japanese patients (Pts) with relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL) pretreated with rituximab
Tobinai, K.
Ogura, M.
Hatake, K.
Kobayashi, Y.
Mori, M.
Uchida, T.
Suzuki, T.
Terui, Y.
Yokoyama, M.
Hotta, T.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[36] Tetravalent anti-CD20/CD3 bispecific antibody for the treatment of B cell lymphoma
Lu, Chia-Yen
Chen, Gregory J.
Tai, Pei-Han
Yang, Yu-Chen
Hsu, Yu-Shen
Chang, Mingi
Hsu, Chuan-Lung
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2016, 473 (04) : 808 - 813
[37] Lisocabtagene maraleucel for relapsed or refractory large B-cell non-Hodgkin lymphoma
Mohty, Razan
Vanegas, Yenny Moreno
Chavez, Julio C.
Kharfan-Dabaja, Mohamed A.
EXPERT REVIEW OF ANTICANCER THERAPY, 2023, 23 (02) : 121 - 126
[38] Economic burden of relapsed/refractory diffuse large B-cell non-Hodgkin's lymphoma (DLBCL): A review of the literature
Slawsky, K. A.
Goss, T. F.
Shinkle, R.
Xu, X.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[39] Anti-CD38 Therapy with Daratumumab for Relapsed/Refractory CD20-Negative Diffuse Large B-Cell Lymphoma
Vockova, P.
Svaton, M.
Karolova, J.
Pokorna, E.
Vokurka, M.
Klener, P.
FOLIA BIOLOGICA, 2020, 66 (01) : 17 - 23
[40] Anti-CD20 monoclonal antibody (rituximab) for therapy of T-cell/histiocyte-rich large B-cell non-Hodgkin lymphoma
Park, ES
Lim, JJ
Kang, HJ
Shin, HY
Ahn, HS
BLOOD, 2005, 106 (11) : 282B - 282B

← 1 2 3 4 5 →